Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17300668 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | Non-Final OA | Massachusetts Institute of Technology |
| 19193454 | ISOLATED IMMUNE CELL EXPRESSING A RECEPTOR, INTERLEUKIN-7, AND CHEMOKINE (C-C MOTIF) LIGAND 19 | Final Rejection | NOILE-IMMUNE BIOTECH, INC. |
| 17047367 | THERAPEUTIC MODULATION OF TUMOR SUPPRESSORS USING EXOSOMES | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17287184 | Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas9 Fusion Protein | Non-Final OA | UNIVERSITY OF ROCHESTER |
| 18449625 | GENETICALLY MODIFIED PRIMARY CELLS FOR ALLOGENEIC CELL THERAPY | Final Rejection | Sana Biotechnology, Inc. |
| 18053160 | GENE THERAPY CONSTRUCTS AND METHODS OF USE | Non-Final OA | Amicus Therapeutics, Inc. |
| 18006555 | LIPID NANOPARTICLE COMPRISING MODIFIED NUCLEOTIDES | Non-Final OA | STRAND THERAPEUTICS INC. |
| 17930705 | SYSTEMS AND METHODS FOR DETECTING TUMOR DNA IN MAMMALIAN BLOOD | Non-Final OA | Gene Solutions Joint Stock Company |
| 17701325 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN B (APOB) GENE EXPRESSION | Non-Final OA | Omega Therapeutics, Inc. |
| 16994283 | USE OF INHIBITORS OF IL-36 PROTEOLYTIC PROCESSING FOR THE TREATMENT AND/OR REDUCTION OF INFLAMMATION | Non-Final OA | THE PROVOST, FILLOWS, FOUNDATIO SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy